"Dexamethasone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An anti-inflammatory 9-fluoro-glucocorticoid.
| Descriptor ID |
D003907
|
| MeSH Number(s) |
D04.210.500.745.432.769.344 D04.210.500.908.238
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Dexamethasone".
Below are MeSH descriptors whose meaning is more specific than "Dexamethasone".
This graph shows the total number of publications written about "Dexamethasone" by people in this website by year, and whether "Dexamethasone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 4 | 6 |
| 1997 | 3 | 1 | 4 |
| 1998 | 2 | 0 | 2 |
| 1999 | 0 | 2 | 2 |
| 2000 | 2 | 3 | 5 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 3 | 4 |
| 2003 | 4 | 1 | 5 |
| 2004 | 1 | 5 | 6 |
| 2005 | 1 | 1 | 2 |
| 2006 | 4 | 3 | 7 |
| 2007 | 4 | 0 | 4 |
| 2008 | 1 | 2 | 3 |
| 2009 | 4 | 2 | 6 |
| 2010 | 2 | 3 | 5 |
| 2011 | 5 | 3 | 8 |
| 2012 | 2 | 5 | 7 |
| 2013 | 1 | 6 | 7 |
| 2014 | 5 | 4 | 9 |
| 2015 | 6 | 4 | 10 |
| 2016 | 2 | 11 | 13 |
| 2017 | 5 | 3 | 8 |
| 2018 | 4 | 5 | 9 |
| 2019 | 2 | 5 | 7 |
| 2020 | 3 | 5 | 8 |
| 2021 | 5 | 3 | 8 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 12 | 12 |
| 2024 | 4 | 4 | 8 |
| 2025 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dexamethasone" by people in Profiles.
-
The Glucocorticoid Receptor Inhibits NRF2-Mediated Expression of SLC7A11. Free Radic Biol Med. 2025 Dec 16; 241:53-63.
-
Individual patient data meta-analysis of NEPA versus aprepitant-based antiemetic regimens for preventing chemotherapy-induced nausea and vomiting. Future Oncol. 2025 Sep; 21(21):2823-2833.
-
NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Med. 2025 Apr; 14(7):e70549.
-
A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for T-Cell Lymphomas. Clin Lymphoma Myeloma Leuk. 2025 May; 25(5):328-336.
-
Mass spectrometry-based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma. Blood. 2024 08 29; 144(9):955-963.
-
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN. Blood Cancer J. 2024 07 08; 14(1):107.
-
Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant. Blood Cancer J. 2024 05 29; 14(1):87.
-
Health-related quality of life in patients with multiple myeloma treated in the phase 3 ATLAS trial of post-transplant maintenance with carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone. Pol Arch Intern Med. 2024 05 28; 134(5).
-
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024 04 22; 14(1):69.
-
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN. Am J Hematol. 2024 07; 99(7):1257-1268.